Baruch S. Blumberg Institute
Dba Baruch S Blumberg Institute
CAGE Code: 47W56
NCAGE Code: 47W56
Status: Active
Type: Commercial Supplier
Dun & Bradstreet (DUNS): 167281851
Summary
Baruch S. Blumberg Institute, Dba Baruch S Blumberg Institute is an Active Commercial Supplier with the Cage Code 47W56 and is tracked by Dun & Bradstreet under DUNS Number 167281851..
Address
3805 Old Easton Rd
Doylestown PA 18902-8400
United States
Points of Contact
No Points of Contact...
Related Information
People who viewed this 'CAGE Code' also viewed...
Sportswear Plus, Inc. New Britain Sales Llc. Breeze-Eastern Div Of D And T Public Safety Equipment Inc Funk R And Co Inc Valjon Industries Inc Computer Interface Instrumention Ide Software Through Pictures T. Schiefer Contractors, Inc. Old Mill Software Co Instrumentation And Controls, Heritage Crafts Knowledge Repository Moria Inc Leading Edge Aviation Inc Stevenson Lumberyard Inc Blum-Moore Reporting Services Inc Tilley Fire Equipment Company Miller Fire Equipment And Air Doylestown Floor Covering Inc Doylestown Mfg Corp Sub Of Thomas
Frequently Asked Questions (FAQ) for CAGE 47W56
- What is CAGE Code 47W56?
- 47W56 is the unique identifier used by NATO Organizations to reference the physical entity known as Baruch S. Blumberg Institute Dba Baruch S Blumberg Institute located at 3805 Old Easton Rd, Doylestown PA 18902-8400, United States.
- Who is CAGE Code 47W56?
- 47W56 refers to Baruch S. Blumberg Institute Dba Baruch S Blumberg Institute located at 3805 Old Easton Rd, Doylestown PA 18902-8400, United States.
- Where is CAGE Code 47W56 Located?
- CAGE Code 47W56 is located in Doylestown, PA, USA.
Contracting History for CAGE 47W56 Most Recent 25 Records
- 75N93023C00003
- To Develop An Orally Available Small Molecule Antiviral Drug, With Treatment Of Yellow Fever Virus Infection As The Primary Indication.
- 17 Mar 2023
- To Develop An Orally Available Small Molecule Antiviral Drug, With Treatment Of Yellow Fever Virus Infection As The Primary Indication.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $5,493,876.00
- Department Of Health And Human Services (Hhs)
- 75N93023C00003
- To Develop An Orally Available Small Molecule Antiviral Drug, With Treatment Of Yellow Fever Virus Infection As The Primary Indication.
- 15 Nov 2022
- To Develop An Orally Available Small Molecule Antiviral Drug, With Treatment Of Yellow Fever Virus Infection As The Primary Indication.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $5,493,876.00
- Department Of Health And Human Services (Hhs)
- 75N93023C00003
- To Develop An Orally Available Small Molecule Antiviral Drug, With Treatment Of Yellow Fever Virus Infection As The Primary Indication.
- 27 Sep 2023
- To Develop An Orally Available Small Molecule Antiviral Drug, With Treatment Of Yellow Fever Virus Infection As The Primary Indication.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $5,493,876.00
- Department Of Health And Human Services (Hhs)